However, PRAME has been shown to be positive in tumors other than melanoma, including many epithelial and non-epithelial tumors and a few sarcomas, leading to variable sensitivity and sensitivity in that regard. In the case presented, we call attention to the strong immunopositivity for the PRAME immunostain in CIC::DUX4 sarcoma. Here, PRAME is linked to melanoma.